Virginia Contract Research Organization Co., Ltd. (VCRO) was authorized by G&E Herbal Biotechnology Co., Ltd., to write and file the full package of phase II IND in common technical document (CTD) format for the purpose of US FDA submission . The phase II clinical study on treatment for Actinic Keratosis has officially gone into effect starting from January 4th 2012, with no questions from the FDA.Related Link:
Congratulations！ IND submission with no questions from the US FDA
Virginia Contract Research Organization Co., Ltd. (VCRO) was authorized by G&E Herbal Biotechnology Co., Ltd., to write and file the full package of phase II IND in common technical document (CTD) format for the purpose of US FDA submission . The phase II clinical study on treatment for Actinic Keratosis has officially gone into effect…